Adverse events in randomized trials: Neglected, restricted, distorted, and silenced

Archives of Internal Medicine

Volumn 169, Issue 19, 2009, Pages 1737-1739

  Ioannidis, John P A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; CLINICAL RESEARCH; EDITORIAL; EVIDENCE BASED PRACTICE; HEALTH CARE POLICY; HEALTH HAZARD; MEDICAL INFORMATION; MEDICAL LITERATURE; PRIORITY JOURNAL;

CONFLICT OF INTEREST; CONSUMER PRODUCT SAFETY; EMPIRICAL RESEARCH; EVIDENCE-BASED MEDICINE; HUMANS; INFORMATION DISSEMINATION; JOURNALISM, MEDICAL; MARKETING OF HEALTH SERVICES; PERIODICALS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 70350517166     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.313     Document Type: Editorial

References (10)

1. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med. 2009;169(19):1756-1761.
2. Ioannidis JP, Evans SJ, Gotzsche PC, et al; CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141(10):781-788.
3. Tsang R, Colley L, Lynd LD. Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials. J Clin Epidemiol. 2009;62(6):609-616.
4. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005; 2(8):e124.
5. Ferreira-Gonzalez I, Permanyer-Miralda G, Busse JW, et al. Composite outcomes can distort the nature and magnitude of treatment benefits in clinical trials. Ann Intern Med. 2009;150(8):566-567.
6. Hernandez AV, Walker E, Ioannidis JP, Kattan MW. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone. Am Heart J. 2008;156(1):23-30.
7. Mahoney MR, Sargent DJ, O'Connell MJ, Goldberg RM, Schaefer P, Buckner JC. Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials. J Clin Oncol. 2005;23(36):9275-9281. (Pubitemid 46260184)
8. Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004; 364(9450):2021-2029. (Pubitemid 39593078)
9. Landefeld CS, Steinman MA. The Neurontin legacy: marketing through misinformation and manipulation. N Engl J Med. 2009;360(2):103-106.
10. Papanikolaou PN, Christidi GD, Ioannidis JP. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ. 2006; 174(5):635-641. (Pubitemid 43341873)